Literature DB >> 8109270

Interstitial irradiation of cerebral gliomas with stereotactically implanted iodine-125 seeds.

J Voges1, H Treuer, W Schlegel, O Pastyr, V Sturm.   

Abstract

Ninety-seven consecutive patients with primarily inoperable or only partially resectable gliomas have been analysed retrospectively. Mean tumour surface doses of 70 Gy (low grade gliomas) and 56 Gy (high grade gliomas) have been applied with stereotactically implanted Iodine-125 seeds at low dose rates. Patients with a glioma grade III or grade IV and permanent seed implantation additionally received a fractionated external beam irradiation. With mean follow-up times of 55.8 months (glioma grade I), 51 months (glioma grade II) and 59.6 months (glioma grade III) the estimated mean survival probabilities are 105 months, 102 months and 65.7 months respectively. In the glioma grade IV group the estimated mean survival time has been 15.6 months after continuous interstitial irradiation (response rate: 36%). Temporary interstitial irradiation in cases with a glioma grade IV (dose rate: 2.1 Gy/day) caused initial tumour shrinkage in 77%. Neurological deficits following radiation induced vasogenic oedema were reversible in 2 patients and irreversible in another 2 patients. 6 years after the Iodine-125 implantation and continuous interstitial irradiation 1 patient developed a severe localised radiation necrosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109270     DOI: 10.1007/978-3-7091-9297-9_25

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  10 in total

1.  Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery.

Authors:  Mohammad Maarouf; Faycal El Majdoub; Christian Bührle; Jürgen Voges; Ralph Lehrke; Martin Kocher; Stefan Hunsche; Harald Treuer; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.

Authors:  Philipp Kickingereder; Christina Hamisch; Bogdana Suchorska; Norbert Galldiks; Veerle Visser-Vandewalle; Roland Goldbrunner; Martin Kocher; Harald Treuer; Juergen Voges; Maximilian I Ruge
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

3.  Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection.

Authors:  Bogdana Suchorska; Maximilian Ruge; Harald Treuer; Volker Sturm; Jürgen Voges
Journal:  Neuro Oncol       Date:  2011-08-25       Impact factor: 12.300

Review 4.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Stefan Grau; Mauritius Hoevels; Harald Treuer; Volker Sturm
Journal:  J Neurooncol       Date:  2011-04-11       Impact factor: 4.130

6.  Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Stefan Grau; Franziska Dorn; Norbert Galldiks; Harald Treuer; Volker Sturm
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

7.  Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors.

Authors:  Faycal El Majdoub; Clemens Neudorfer; Tobias Blau; Martin Hellmich; Christian Bührle; Martina Deckert; Volker Sturm; Mohammad Maarouf
Journal:  Strahlenther Onkol       Date:  2015-08-26       Impact factor: 3.621

8.  Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III.

Authors:  B Suchorska; C Hamisch; H Treuer; K Mahnkopf; R E Lehrke; M Kocher; M I Ruge; J Voges
Journal:  J Neurooncol       Date:  2016-07-15       Impact factor: 4.130

9.  Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Thorsten Simon; Harald Treuer; Volker Sturm
Journal:  J Neurooncol       Date:  2012-05-12       Impact factor: 4.130

10.  Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation.

Authors:  Maximilian I Ruge; Philipp Kickingereder; Stefan Grau; Harald Treuer; Volker Sturm; Juergen Voges
Journal:  Radiat Oncol       Date:  2012-06-19       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.